Updates and Advances in Multiple Sclerosis Neurotherapeutics
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 1×
“To better reflect underlying MS pathology and corresponding clinical and radiographic activity, the definition of clinical phenotypes was recently updated [10,11].”
BackgroundDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Bjornevik, K., Cortese, M., Healy, B. C., Kuhle, J., Mina, M. J., Leng, Y., Elledge, S. J., Niebuhr, D. W., Scher, A. I., Munger, K. L., et al. (2022) · Science · doi:10.1126/science.abj8222 · Cited by 2,049
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 3×
“These studies showed that compared with IFN-β1a, ocrelizumab was associated with significantly reduced ARR (by 45%) and reduced risk of CDP (by 34%) at 6 months; it significantly reduced the number of GdE lesions (by 95%) and new/enlarging T2 lesions (by about 80%) [68].”
MethodResultOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 4×
“In ORATORIO, ocrelizumab reduced CDP in PPMS versus placebo [27,92].”
BackgroundInfluentialCohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205 · cited 2×
“Phase III clinical trials CARE-MS I and CARE-MS II demonstrated high relapse-free rates (78 and 65%, respectively), compared with subcutaneous IFN-β1a, with a significant reduction in the number of new T2 and GdE lesions and reduction in brain volume loss in previously treated MS, including patients with breakthrough…”
ResultColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198 · cited 2×
“Phase III clinical trials CARE-MS I and CARE-MS II demonstrated high relapse-free rates (78 and 65%, respectively), compared with subcutaneous IFN-β1a, with a significant reduction in the number of new T2 and GdE lesions and reduction in brain volume loss in previously treated MS, including patients with breakthrough…”
ResultPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 1×
“While OPCs are abundant in the CNS and present in chronic MS lesions, remyelination is insufficient, especially in late-stage and progressive MS [149].”
BackgroundKappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Cited by
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Greenberg, B. M. (2024) · Neurologic Clinics · doi:10.1016/j.ncl.2023.07.006 · Cited by 10
Neuroinflammation-on-a-chip for multiple sclerosis research: a narrative review
Berjaoui, C., Kachouh, C., Joumaa, S., Hussein Ghayyad, M., Abate Bekele, B., Ajirenike, R., Al Maaz, Z., Awde, S., Wojtara, M., Nazir, A., et al. (2024) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000002231 · Cited by 4
“In vitro and ex vivo models show that these medications have direct or indirect effects on the immune system and CNS cells, which may help explain how they cause remyelination in animal models of MS [25,26] (Fig.”
Background
Metadata
- Authors
- Amin, M., & Hersh, C. M.
- Venue
- Neurodegenerative Disease Management
- Publisher
- Informa UK Limited
- Published
- 2022-10-31
- Volume
- 13
- Issue
- 1
- Pages
- 47-70
- ISSN
- 1758-2024 (ISSN-L)
- 1758-2032
- OpenAlex
- W4307778335
- Cited by
- 164
- References
- 19
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updates and Advances in Multiple Sclerosis Neurotherapeutics. https://app.cochat.ai/papers/10.2217/nmt-2021-0058
- The paper
- Amin, M., & Hersh, C. M. (2023). Updates and Advances in Multiple Sclerosis Neurotherapeutics. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2021-0058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.